PRESENT
This retrospective analysis identified similar indications for primary and delayed amputation. 4 The most common indication was loss of limb function from direct tumor invasion or anticipated loss of function due to lack of a viable function-sparing surgical salvage option. Notably, survival did not differ between early and delayed amputation cohorts measured from the time of diagnosis, although a trend toward improved outcome was observed with primary amputation. Additionally, the delayed cohort had a higher rate of post-amputation distant metastases.
Prior studies have demonstrated decreased survival for patients requiring primary amputation, and the findings of the current study suggest that delayed amputation also is an adverse prognostic marker. Notably, the cohort with delayed amputation was more likely to present with proximal tumors and thus required more morbid amputations at the time of recurrence.
FUTURE
The optimal management of patients with ES requiring amputation in the modern era remains an important area of investigation. The results of this and other studies demonstrate that patients who require amputation for ES have a worse outcome despite a lower rate of local recurrence, indicating a fundamental difference in tumor biology. Recent advances in genomics, proteomics, and bioinformatics may allow clinicians to better characterize and target unique adverse biologic traits of ES tumors that require amputation. Such findings are critical to the development of better systemic therapies, which are ultimately needed to improve outcomes for this patient population.
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